Co-Diagnostics Joins WHO/Unitaid/UNAIDS Meeting to Push Tuberculosis Diagnostics — Co-Diagnostics, Inc. (Co-Dx)

Event summary

Co-Diagnostics to participate in WHO/Unitaid/UNAIDS Annual Consultation Meeting on September 17-18, 2026 in Geneva.
Joseph Featherstone, EVP of Business Development, representing the company.
WHO issued guidance supporting near-point-of-care molecular diagnostics and tongue swab sampling for tuberculosis testing.
Co-Dx™ PCR MTB test under clinical performance studies in India via joint venture CoSara Diagnostics.

The big picture

Co-Diagnostics' participation in the WHO/Unitaid/UNAIDS meeting underscores the growing emphasis on equitable access to tuberculosis diagnostics. The company's alignment with WHO guidance on near-point-of-care diagnostics positions it within a broader trend of decentralizing healthcare solutions. Success here could expand its footprint in global health markets, particularly in regions with high tuberculosis prevalence.

What we're watching

Regulatory Alignment: Whether Co-Dx™ PCR MTB test can secure regulatory approvals based on WHO guidance.
Clinical Validation: The pace at which clinical performance studies in India yield conclusive results.
Market Adoption: How global health organizations' endorsement will impact commercialization timelines.